Formuepleje A 13F: Cuts TMO Stake by $26M

Formuepleje A/S lowered its investment in Thermo Fisher Scientific Inc. TMO, according to a filing on October 15, 2026. Keep in mind that 13F filings look backward at a prior period and may not reflect the investor's exact current holdings today.

Inside Formuepleje A/S's Thermo Fisher Scientific Trade

Formuepleje A/S trimmed its position in the healthcare giant by 31.2%, selling 39,093 shares during the period. The fund ended the quarter with 86,028 shares of Thermo Fisher Scientific Inc. valued at about $58.1 million.

Other Institutional Activity in Thermo Fisher Scientific

Blackrock Inc. grew its holdings by 492,913 shares, ending with 30,919,632 shares worth about $21.3 billion. Vanguard Capital Management LLC reduced its stake by 4,856 shares, ending with 24,276,316 shares worth about $16.8 billion. State Street Corporation grew its holdings by 93,700 shares, ending with 16,825,879 shares worth about $11.6 billion. FMR, LLC grew its holdings by 3,308,292 shares, ending with 14,084,488 shares worth about $9.7 billion. Morgan Stanley reduced its stake by 99,940 shares, ending with 10,763,066 shares worth about $7.4 billion.

Thermo Fisher Scientific Inc. Stock Down 1.6%

Thermo Fisher Scientific Inc. shares recently traded around $685.18 as of October 16, 2026. The stock sits about 25.3% above its 200-day moving average and trades not far from its 52-week high of $704.00.

Recent Earnings

Thermo Fisher Scientific generated $46.3 billion in trailing-twelve-month revenue with earnings of $18.58 per share. The company reports its next financial results on October 21, 2026.

Dividend

Thermo Fisher Scientific pays an annual dividend rate of $1.88 per share, which translates to a dividend yield of 0.27%. The company currently uses about 9.7% of its earnings to fund this payout.

Insider Buying and Selling at Thermo Fisher Scientific Inc.

Company insiders executed several transactions prior to the filing. Lisa P Britt sold 11,440 shares on August 19, 2026, for about $7.0 million. Chief Executive Officer Marc N Casper sold 20,000 shares on August 21, 2026, valued at roughly $12.6 million, and a further 275 shares on August 24, 2026. Gianluca Pettiti sold 4,133 shares on August 31, 2026, for about $2.5 million.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. Piper Sandler maintained a Neutral rating with a $600 target on July 27, 2026. CLSA initiated coverage with an Outperform rating and a $748 target on September 3, 2026. Barclays maintained an Overweight rating with a $750 target on October 7, 2026. Morgan Stanley kept an Overweight rating with a $730 target on October 13, 2026, while TD Cowen maintained a Buy rating and a $760 target on the same day. The stock currently holds a consensus strong buy rating with an average price target of $688.69 across 26 analysts.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. operates in the healthcare sector, focusing on diagnostics and research. Headquartered in Waltham, Massachusetts, the firm provides analytical instruments, life sciences solutions, and laboratory products to customers around the globe.

Bottom Line

Investors will look closely at the company's upcoming earnings release on October 21, 2026, for fresh signals on growth. Future regulatory filings will show whether institutional sentiment around the stock continues to shift. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.